Grifols, S.A.

GRFS Healthcare Drug Manufacturers General

Grifols, S.A.’s revenue for fiscal 2025 (year ended December 2025) was $8.5 billion, up 9.07% from fiscal 2024. In the quarter to June 2026, revenue grew 5.76%, EPS grew 466.9%, free cash flow grew 300.5% and total debt was flat, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.

7.64 0.10 +1.33%
Market cap
$2.0B
P/E
8.5×
Fwd P/E
—
Dividend yield
1.24%
F-score
5/9
Altman Z
1.38
Beneish M
−2.59
Dividend safety
54/100
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
— 8.88 10.35 24.51

+8 more quarters

P/S ratio
— 0.63 0.75 0.84
P/FCF ratio
— 9.06 9.85 14.04
P/Operating CF
— 42.39 13.70 17.58
P/B ratio
— 0.59 0.74 0.78
Price to Tangible BV
— 0.00 0.00 0.00
EV/Sales
— 1.84 1.91 2.10
EV/EBITDA
— 8.23 8.51 9.61
EV/Operating CF
— 13.57 13.76 16.37
EV/FCF
— 26.37 25.24 35.25
Quick Ratio
0.70 0.76 0.80 0.85
Current Ratio
2.37 2.47 2.51 2.48
Net Debt/EBITDA
0.00 25.10 22.27 19.13
Debt/Assets
46.57% 48.16% 48.92% 48.80%
Debt/Equity
1.17 1.23 1.27 1.28
Asset Turnover
0.00 0.38 0.38 0.35
Operating CF/Net income
0.00 1.51 4.20 2.63
Capex/Depreciation
(1.09) (0.87) (1.02) (1.02)
Interest Coverage
— 1.81 1.68 2.27
Research and Development Expense of Revenue
— 5.29% 6.87% 5.20%
Selling, General and Administrative Expense of Revenue
— 16.53% 14.10% 15.28%
Intangible Assets out of Total Assets
0.49 0.53 0.49 0.53
Share Based Compensation of Revenue
— 0.00% 0.00% 0.00%
Graham Net Nets
— (1.50) (1.25) (1.19)
Graham Number
— 0.00 16.03 0.00
Earnings Yield
— 11.26% 9.66% 4.08%
Free Cash Flow Yield
— 11.04% 10.15% 7.12%
Revenue per Share
— 0.00 3.39 0.00
Operating CF per Share
0.00 0.00 0.68 0.00
Capex per Share
0.00 0.00 (0.20) 0.00
Free Cash Flow per Share
0.00 0.00 0.48 0.00
Cash per Share
0.00 0.00 1.43 0.00
Shareholders Equity per Share
0.00 0.00 12.64 0.00
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
0.00 0.00 12.64 0.00
Free Cash Flow
128.91 23.41 327.96 259.44
Working Capital
3,568.33 3,663.35 3,456.43 3,733.38
Capital Expenditures
(134.18) (105.34) (136.42) (130.72)
Net Current Asset Value
(7,912.18) (8,165.88) (7,959.40) (8,132.08)
EV/EBIT
— 11.21 11.59 11.94
Capex to Sales
0.00 0.05 0.06 0.06
Price to Operating Income
— 3.85 4.52 4.76
Other line items
Average Receivables
997.85 1,031.48 960.73 1,037.27
Average Payables
968.46 — 865.12 —
Average Inventory
3,929.75 3,880.29 3,764.44 3,907.92
Average Assets
22,899.16 22,800.10 22,303.03 23,606.37
Average Common Equity
8,951.89 8,960.87 7,242.39 8,878.00

Fold the line items

Columns are period end dates